Abstract:Pancreatic cancer is characterized by fibrosis/desmoplasia in the tumor microenvironment, which is primarily mediated by pancreatic stellate cells and cancer-associated fibroblasts. HGF/c-MET signaling, which is instrumental in embryonic development and wound healing, is also implicated for its mitogenic and motogenic properties. In pancreatic cancer, this pathway, along with its downstream signaling pathways, is associated with disease progression, prognosis, metastasis, chemoresistance, and other tumor-related factors. Other features of the microenvironment in pancreatic cancer with the HGF/c-MET pathway include hypoxia, angiogenesis, metastasis, and the urokinase plasminogen activator positive feed-forward loop. All these attributes critically influence the initiation, progression, and metastasis of pancreatic cancer. Therefore, targeting the HGF/c-MET signaling pathway appears promising for the development of innovative drugs for pancreatic cancer treatment. One of the primary downstream effects of c-MET activation is the MAPK/ERK (Ras, Ras/Raf/MEK/ERK) signaling cascade, and MEK (Mitogen-activated protein kinase kinase) inhibitors have demonstrated therapeutic value in RAS-mutant melanoma and lung cancer. Trametinib is a selective MEK1 and MEK2 inhibitor, and it has evolved as a pivotal therapeutic agent targeting the MAPK/ERK pathway in various malignancies, including BRAF-mutated melanoma, non-small cell lung cancer and thyroid cancer. The drug's effectiveness increases when combined with agents like BRAF inhibitors. However, resistance remains a challenge, necessitating ongoing research to counteract the resistance mechanisms. This review offers an in-depth exploration of the HGF/c-MET signaling pathway, trametinib's mechanism, clinical applications, combination strategies, and future directions in the context of pancreatic cancer.

What problem does this paper attempt to address?

This paper attempts to address several key issues in the treatment of pancreatic cancer, focusing primarily on the HGF/c-MET signaling pathway and its role in the progression of pancreatic cancer. Specifically: 1. **Challenges in the Treatment of Pancreatic Cancer**: - Pancreatic cancer is a highly invasive disease, and its complex tumor microenvironment (especially fibrosis/stromal reaction) makes early detection and treatment very difficult. - Most patients are diagnosed at a late stage, at which point they are no longer suitable for curative surgical resection. - Pancreatic cancer exhibits significant resistance to standard chemotherapy and immunotherapy (such as immune checkpoint inhibitors). 2. **Role of the HGF/c-MET Signaling Pathway**: - The HGF/c-MET signaling pathway plays an important role in embryonic development and wound healing, but in pancreatic cancer, this pathway and its downstream signaling pathways are associated with disease progression, poor prognosis, metastasis, chemotherapy resistance, and other tumor-related factors. - This pathway is also closely related to other features of the tumor microenvironment (such as hypoxia, angiogenesis, metastasis, and the urokinase plasminogen activator positive feedback loop), which collectively influence the initiation, progression, and metastasis of pancreatic cancer. 3. **Mechanism of Action of Trametinib**: - Trametinib is a selective inhibitor of MEK1 and MEK2, which inhibits the proliferation and survival of cancer cells by blocking the MAPK/ERK signaling pathway. - Trametinib can not only directly inhibit the division, angiogenesis, and metastasis of cancer cells but also significantly alter the tumor microenvironment, including regulating the activity of fibroblasts and immune cells, which play a key role in cancer progression and treatment response. - When used in combination with other drugs (such as BRAF inhibitors), Trametinib shows more significant effects, especially in cases resistant to conventional therapies. 4. **Clinical Applications and Future Directions**: - Multiple clinical trials are currently underway to evaluate the efficacy of Trametinib in different stages and types of pancreatic cancer, whether as monotherapy or in combination with other drugs. - Research is also focused on overcoming the resistance mechanisms of Trametinib to improve its long-term efficacy in the treatment of pancreatic cancer. In summary, this paper explores the role of the HGF/c-MET signaling pathway in pancreatic cancer and evaluates the potential of Trametinib as a MEK inhibitor in the treatment of pancreatic cancer, aiming to provide new therapeutic avenues for this challenging disease.

Pancreatic Cancer Treatment Targeting the HGF/c-MET Pathway: The MEK Inhibitor Trametinib

Potential Therapeutics Specific to C-Met/ron Receptor Tyrosine Kinases for Molecular Targeting in Cancer Therapy.

Aberrant RON and MET Co-overexpression As Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.

HGF/c-Met pathway inhibition combined with chemotherapy increases cytotoxic T-cell infiltration and inhibits pancreatic tumour growth and metastasis

A Subset of Metastatic Pancreatic Ductal Adenocarcinomas Depends Quantitatively on Oncogenic Kras/Mek/Erk-Induced Hyperactive Mtor Signalling

CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma

Progress and Challenge in Development of Biotherapeutics Targeting MET Receptor for Treatment of Advanced Cancer.

Targeting HGF/c-MET Axis in Pancreatic Cancer

Cmet As A Potential Therapeutic Target In Gastric Cancer

Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer

Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel in KRAS -mutated colorectal cancer

Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis

Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy

Trametinib in the treatment of multiple malignancies harboring MEK1 mutations

Targeting the HGF/c-MET Pathway: Stromal Remodelling in Pancreatic Cancer.

Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS -mutant lung cancer

Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer

Trametinib potentiates anti-PD-1 efficacy in tumors established from chemotherapy-primed pancreatic cancer cells

Synergistic Blocking of RAS Downstream Signaling and Epigenetic Pathway in KRAS Mutant Pancreatic Cancer.

Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123)

Dipyridamole Enhances the Cytotoxicities of Trametinib against Colon Cancer Cells through Combined Targeting of HMGCS1 and MEK Pathway